Sponsored For
Beginners Choice

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aphria Inc is a drug manufacturers-specialty & generic business based in the US. Aphria shares (APHA) are listed on the NASDAQ and all prices are listed in US Dollars. Aphria employs 1,200 staff and has a market cap (total outstanding shares value) of USD$2.1 billion.
Since the stock market crash in March caused by coronavirus, Aphria's share price has had significant positive movement.
Its last market close was USD$4.68, which is 11.54% up on its pre-crash value of USD$4.14 and 140.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.95.
If you had bought USD$1,000 worth of Aphria shares at the start of February 2020, those shares would have been worth USD$552.17 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,017.39.
Latest market close | USD$4.68 |
---|---|
52-week range | USD$1.95 - USD$8.88 |
50-day moving average | USD$7.1661 |
200-day moving average | USD$5.2981 |
Wall St. target price | N/A |
PE ratio | 23.8462 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.299 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the last close of $4.68
1 week (2021-01-12) | -50.37% |
---|---|
1 month (2020-12-18) | -38.82% |
3 months (2020-10-19) | 4.68 |
6 months (2020-07-17) | -8.24% |
1 year (2020-01-17) | -11.20% |
---|---|
2 years (2019-01-18) | -29.94% |
3 years (2018-01-19) | -73.60% |
5 years (2016-01-19) | 457.08% |
Valuing Aphria stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aphria's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aphria's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Aphria shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gross profit TTM | USD$191 million |
---|---|
Return on assets TTM | 0.53% |
Return on equity TTM | -5.89% |
Profit margin | -18.93% |
Book value | $5.345 |
Market capitalisation | USD$2.1 billion |
TTM: trailing 12 months
There are currently 21.7 million Aphria shares held short by investors – that's known as Aphria's "short interest". This figure is 12.6% down from 24.8 million last month.
There are a few different ways that this level of interest in shorting Aphria shares can be evaluated.
Aphria's "short interest ratio" (SIR) is the quantity of Aphria shares currently shorted divided by the average quantity of Aphria shares traded daily (recently around 12.1 million). Aphria's SIR currently stands at 1.8. In other words for every 100,000 Aphria shares traded daily on the market, roughly 1800 shares are currently held short.
However Aphria's short interest can also be evaluated against the total number of Aphria shares, or, against the total number of tradable Aphria shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aphria's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Aphria shares in existence, roughly 80 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aphria shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aphria.
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Takeda Pharmaceutical shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing Heat Biologics shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.